Cite
HARVARD Citation
Aroda, V. et al. (2020). Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: A patient‐level, pooled analysis of the SUSTAIN 1‐5 trials. Diabetes, obesity & metabolism. 22 (3), pp. 303-314. [Online].